Riluzole Selective Antioxidant Effects in Cell Models Expressing Amyotrophic Lateral Sclerosis Endophenotypes
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: Until recently, riluzole was the only drug licensed for amyotrophic lateral sclerosis (ALS). In spite of its efficacy, the mechanism of action remains elusive, and both blocking of glutamate release and antioxidant properties have been postulated. Here we characterized human SH-SY5Y neuroblastoma cell lines, taking advantage of their insensitivity to excitotoxic insults, in order to selectively assess the presence of a direct antioxidant effect of riluzole. Methods: SH-SY5Y cells, either parental or overexpressing the G93A SOD1 mutation, were exposed for 24 hours to the selected stimuli. Results: Riluzole (1‒10 M) was able to counteract the effects of H2O2 exposure (200 M/24 hr), limiting both cell death and whole-cell reactive oxygen species (ROS) increase. The same experiments were repeated using SH-SY5Y cells carrying the familial ALS-related G93A-SOD1 mutation and constitutively expressing two-fold increased whole-cell ROS levels with respect to wild-type cells: riluzole was ineffective in this paradigm. Analogously, riluzole was ineffective in preventing cell death induced by exposing SH-SY5Y cells to 3-morpholino-sydnonimine (SIN-1, 1.5 mM/24 hr), a reactive nitrogen species (RNS) donor. Conclusion: Our data support a direct antioxidant action of riluzole. Furthermore, the lack of efficacy of riluzole observed in the SOD1 cell model mirrors the lack of efficacy already demonstrated in cognate mouse models of ALS, plausibly reflecting differences in the underlying pathogenic mechanisms. Finally, riluzole inefficacy against nitrosative stress might support the idea that a combined therapeutic intervention may result more effective in ALS patients, as in the case of co-administration of edaravone, a drug known to reduce RNS.
Abstract
Objective: Until recently, riluzole was the only drug licensed for amyotrophic lateral sclerosis (ALS). In spite of its efficacy, the mechanism of action remains elusive, and both blocking of glutamate release and antioxidant properties have been postulated. Here we characterized human SH-SY5Y neuroblastoma cell lines, taking advantage of their insensitivity to excitotoxic insults, in order to selectively assess the presence of a direct antioxidant effect of riluzole. Methods: SH-SY5Y cells, either parental or overexpressing the G93A SOD1 mutation, were exposed for 24 hours to the selected stimuli. Results: Riluzole (1‒10 M) was able to counteract the effects of H2O2 exposure (200 M/24 hr), limiting both cell death and whole-cell reactive oxygen species (ROS) increase. The same experiments were repeated using SH-SY5Y cells carrying the familial ALS-related G93A-SOD1 mutation and constitutively expressing two-fold increased whole-cell ROS levels with respect to wild-type cells: riluzole was ineffective in this paradigm. Analogously, riluzole was ineffective in preventing cell death induced by exposing SH-SY5Y cells to 3-morpholino-sydnonimine (SIN-1, 1.5 mM/24 hr), a reactive nitrogen species (RNS) donor. Conclusion: Our data support a direct antioxidant action of riluzole. Furthermore, the lack of efficacy of riluzole observed in the SOD1 cell model mirrors the lack of efficacy already demonstrated in cognate mouse models of ALS, plausibly reflecting differences in the underlying pathogenic mechanisms. Finally, riluzole inefficacy against nitrosative stress might support the idea that a combined therapeutic intervention may result more effective in ALS patients, as in the case of co-administration of edaravone, a drug known to reduce RNS.
참고문헌 (20)
- Miller RG, "Riluzole for amyotrophic lateral sclerosis (ALS)", motor neuron disease (MND), 2012, pp.(3), CD001447~
- Wokke J, "Riluzole", Lancet, 348, pp.795~799 (1996)
- Azbill RD, "Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes", Brain Res, 871, pp.175~180 (2000)
- Koh JY, "Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons", J Neurochem, 72, pp.716~723 (1999)
- Storch A, "Protective effects of riluzole on dopamine neurons : involvement of oxidative stress and cellular energy metabolism", J Neurochem, 75, pp.2259~2269 (2000)
- Yoshino H, "Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis(Phase II study)", Amyotroph Lateral Scler, 7, pp.241~245 (2006)
- Nagase M, "Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration", Redox Rep, 21, pp.104~112 (2016)
- Aguirre T, "Increased sensitivity of fibroblasts from amyotrophic lateral sclerosis patients to oxidative stress", Ann Neurol, 43, pp.452~457 (1998)
- Sala G, "Impairment of glutamate transport and increased vulnerability to oxidative stress in neuroblastoma SH-SY5Y cells expressing a Cu, Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis", Neurochem Int, 46, pp.227~234 (2005)
- Sala G, "Rotenone down-regulates HSPA8", hsc70 chaperone protein in vitro : a new possible toxic mechanism contributing to Parkinson's disease, 2016, pp.54, 161~169
- Sala G, "Lack of evidence for oxidative stress in sporadic amyotrophic lateral sclerosis fibroblasts", Neurodegener Dis, 6, pp.9~15 (2009)
- Beretta S, "Mitochondrial dysfunction due to mutant copper", zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-acetylcysteine, 2003, pp.13, 213~221
- Hardiman O, "Amyotrophic lateral sclerosis", Nat Rev Dis Primers, 3, pp.17085~ (2017)
- Tremolizzo L, "Amyotrophic lateral sclerosis: new research", pp.71~109 (2005), Nova Science Publishers
- Bondy SC, "The relationship between excitotoxicity and oxidative stress in the central nervous system", Free Radic Biol Med, 14, pp.633~642 (1993)
- Soon CP, "Diacetylbis(N(4)-methylthiosemicarbazonato)copper(II)(CuII(atsm))protects against peroxynitrite-induced nitrosative damage and prolongs survival in amyotrophic lateral sclerosis mouse model", J Biol Chem, 286, pp.44035~44044 (2011)
- Bellezza I, "Peroxynitrite activates the NLRP3 inflammasome cascade in SOD1(G93A)mouse model of amyotrophic lateral sclerosis", Mol Neurobiol, 55, pp.2350~2361 (2018)
- Nakamura T, "'SNO'-Storms compromise protein activity and mitochondrial metabolism in neurodegenerative disorders", Trends Endocrinol Metab, 28, pp.879~892 (2017)
- Hogg MC, "Riluzole does not improve lifespan or motor function in three ALS mouse models", Amyotroph Lateral Scler Frontotemporal Degener, 19, pp.438~445 (2018)
- Ahmadi M, "Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis : a pilot randomized clinical trial", Neurotherapeutics, 15, pp.430~438 (2018)